溃疡性结肠炎的非手术治疗进展(6)
[28] Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease . World J Gastroenterol,2018,24(17):1868-1880.
[29] 李美, 苗建壮, 许述. 炎症性肠病小分子免疫抑制剂的研发进展. 药学学报,2018,53(8):1290-1302.
[30] Fiorino G, D’Amico F, Italia A, Gilardi D, Furfaro F, Danese S. JAK inhibitors: novel developments in management of ulcerative colitis. Best Pract Res Clin Gastroenterol,2018,32-33:89-93.
[31] 廖诗乐, 陈白莉, 曾志荣. 粪菌移植治疗炎症性肠病的现状和问题. 新医学,2014,45(9):569-572.
[32] Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, L?wenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM, Zoetendal EG, D’Haens GR, Ponsioen CY. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology,2015,149(1):110-118.e4.
[33] Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic review: adverse events of fecal microbiota transplantation. PLoS One,2016,11(8):e0161174.
[34] Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, Li P, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open,2016,4(6):E610-E613.
[35] Lai YM, Yao WY, He Y, Jiang X, Gu YB, Chen MH, Liu YL, Yuan YZ, Qian JM. Adsorptive granulocyte and monocyte apheresis in the treatment of ulcerative colitis: the first multicenter study in China. Gut Liver,2017,11(2):216-225.
[36] Markovic BS, Kanjevac T, Harrell CR, Gazdic M, Fellabaum C, Arsenijevic N, Volarevic V. Molecular and cellular mechanisms involved in mesenchymal stem cell-based therapy of inflammatory bowel diseases. Stem Cell Rev,2018,14(2):153-165.
(收稿日期:2018-10-08)
(本文編辑:杨江瑜), http://www.100md.com(冯锦霞?夏忠胜)
[29] 李美, 苗建壮, 许述. 炎症性肠病小分子免疫抑制剂的研发进展. 药学学报,2018,53(8):1290-1302.
[30] Fiorino G, D’Amico F, Italia A, Gilardi D, Furfaro F, Danese S. JAK inhibitors: novel developments in management of ulcerative colitis. Best Pract Res Clin Gastroenterol,2018,32-33:89-93.
[31] 廖诗乐, 陈白莉, 曾志荣. 粪菌移植治疗炎症性肠病的现状和问题. 新医学,2014,45(9):569-572.
[32] Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, L?wenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM, Zoetendal EG, D’Haens GR, Ponsioen CY. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology,2015,149(1):110-118.e4.
[33] Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic review: adverse events of fecal microbiota transplantation. PLoS One,2016,11(8):e0161174.
[34] Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, Li P, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open,2016,4(6):E610-E613.
[35] Lai YM, Yao WY, He Y, Jiang X, Gu YB, Chen MH, Liu YL, Yuan YZ, Qian JM. Adsorptive granulocyte and monocyte apheresis in the treatment of ulcerative colitis: the first multicenter study in China. Gut Liver,2017,11(2):216-225.
[36] Markovic BS, Kanjevac T, Harrell CR, Gazdic M, Fellabaum C, Arsenijevic N, Volarevic V. Molecular and cellular mechanisms involved in mesenchymal stem cell-based therapy of inflammatory bowel diseases. Stem Cell Rev,2018,14(2):153-165.
(收稿日期:2018-10-08)
(本文編辑:杨江瑜), http://www.100md.com(冯锦霞?夏忠胜)